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ABSTRACT 
Drug induced gingival enlargement is the term now used to describe medication related gingival hypertrophy or hyperplasia, a condition commonly induced by 
three main classes of drugs: anticonvulsants, antihypertensive calcium channel blockers and the immunosuppressant cyclosporine. The pathogenesis of drug-
induced gingival enlargement is uncertain and there appears to be no unifying hypothesis that links together the three commonly implicated drugs. Various risk 
factors and etiologic agents like age, drug doses, genetic factors, plaque induced 
inflammation etc have been proposed. Management of such condition when it interferes with aesthetic, function and occlusion includes non surgical and 
surgical intervention. It is important that the health practitioner is aware of the potential etiologic agents and characteristic features in order to be able to 
accurately diagnose and successfully manage such patients. 
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INTRODUCTION 
There  is  an  ever  increasing  number  of  medications  which 
may  induce  over  growth  of  the  gingiva,  although  a  large 
range of pathological and idiopathic reactions can also result 
in  gingival  overgrowth.  This  review  concentrates  on  the 
various  over  growths  associated  with  pharmaceuticals,  and 
their clinical management. The medication-induced gingival 
overgrowths occur as a side effect of drugs used mainly for 
non-dental treatment for which the gingival tissue is not the 
intended target organ. 
‘Overgrowth’  is  the  preferred  term  for  many  of  these 
medication  -  related  conditions  previously  labelled  as 
‘gingival  hyperplasia’  and  ‘gingival  hypertrophy’.  These 
terms do not truly reflect our current understanding of the 
macroscopically enlarged, histologically altered, gingiva. 
Drugs  associated  with  gingival  overgrowth  can  be 
categorized  broadly  into  three  major  groups  according  to 
their  therapeutic  actions,  namely  anticonvulsants, 
immunosupressants and calcium channel blockers 
Although the pharmacologic effect of each of these drugs is 
different and directed toward various primary target tissues, 
all of them seem to act similarly on a secondary target tissue, 
i.e., the gingival connective tissue, causing common clinical 
and histopathological findings. 
PREVALENCE 
 There is wide variation in the literature regarding prevalence 
of  drug  induced  gingival  hyperplasia.  For  phenytoin,  the 
figure  of  50%  is  quoted,  whereas  for  cyclosporine  and 
calcium channel blockers (CCBs) a much lower prevalence 
of  30%  and  10%  respectively  is  reported
1.  Among  CCBs, 
prevalence  of  gingival  hyperplasia  is  reported  to  be 
maximum for nifedipine (30-50%) treatment as compared to 
other  CCBs
2.  Reported  prevalence  of  gingival  overgrowth 
(GO)  after  cyclosporine  therapy  varies  between  8-81%. 
However, in a well controlled study, the overall prevalence 
was reported to be 21%
3. Recent studies show that severity of 
GO  is  increased  when  patients  taking  cyclosporine  in 
combination  with  CCBs
4.  Gingival  hyperplasia  is  a  rare 
condition.  No  population  based  or  epidemiologic  data  is 
available in United States and Worldwide
5. In India 57% of 
epileptic  children  aged  8-13  years  who  were  undergoing 
phenytoin  treatment,  developed  GO  within  6  months  of 
treatment
5. Prevalence of phenytoin induced GO is estimated 
between 15-50 % in patients taking drug. Prevalence of GO 
in  cyclosporine  recipient  transplant  patients  is  27  %. 
Incidence of GO has been reported as 10-20 % in patients 
treated with CCBs
5. 
RISK  FACTORS  FOR  DRUG  INDUCED  GINGIVAL 
OVERGROWTH  
Age - Age has been considered an important risk factor for 
drug induced GO particularly for phenytoin and cyclosporine 
while age is not a risk factor for CCBs
1. Phenytoin induced 
GO mainly observed in teenagers. Cyclosporine induced GO 
is more (52%) common in paediatric organ transplant patients 
as compared to adults
6.7.  
Sex/  Race  –  After  cyclosporine  treatment,  males  were  at 
greater risk from developing GO than females
7. Males were 
shown to be 3 times more likely than females to develop GO 
when  treated  with  CCBs
1.  Gender  and  race  were  not 
important risk factors for gingival changes to phenytoin
7. No 
racial prediction exists for the onset of drug induced GO
5.  
Drug variables – Doses, duration of treatment, serum and 
salivary concentrations remain controversial issue as far as 
gingival hyperplasia is concerned
7.  
Drug combinations – There is evidence that combination of 
nifedipine  and  cyclosporine  in  organ  transplant  patients 
produces  more  GO  than  if  each  drug  was  used  alone
8. 
Incidence of this side effects was found to be higher when 
multiple anticonvulsants were taken together with phenytoin
7.  
Periodontal variables – Plaque and gingival inflammation 
exacerbate  drug  induced  GO.  However,  conflicting  reports 
are available in case of cyclosporine induced GO. Plaque and 
gingival inflammation are also important risk factor for GO 
associated with CCBs.  
Genetic  factors-  Cytochrome  P-450  gene  polymorphism 
which results in inter-individual variation in enzyme activity 
may be a risk factor for drug induced GO
7. Genetic markers 
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antigen (HLA) expression may be a risk factor involved in 
drug  induced  GO.  Various  forms  of  HLA  eg.  HLA-DR1, 
HLA-DR2, HLA-A19 and HLA-B37 have been identified but 
their exact role as risk factor is not completely understood
6.9. 
TYPES OF PHARMACOLOGIC AGENTS 
Anticonvulsants 
Phenytoin remains the drug of choice for treatment for grand 
mal, temporal lobe, and psychomotor seizures since it was 
first introduced in the 1930s
10. In the U.S., about 2 million 
patients  take  phenytoin  for  seizure  control
11.  The  first 
reported cases of phenytoin associated enlargement appeared 
more than 6 decades ago
10. Since then, other anticonvulsant 
agents have been introduced that have frequently been linked 
to clinically significant forms of gingival enlargement. For 
example,  gingival  enlargement  cases  after  chronic  use  of 
valproic  acid,  carbamazepine,  or  phenobarbitone  in  adult 
patients have been reported but are rare or have been poorly 
documented
12-14. Vigabatrin is a relatively new antiepileptic 
agent that can cause gingival overgrowth
15. However, there 
has been no systematic attempt to study gingival enlargement 
in patients taking vigabatrin. 
Calcium Channel Blockers 
Antihypertensive drugs in the calcium channel blocker group 
are used extensively in elderly patients who have angina or 
peripheral vascular disease
10,16. The total number of annual 
prescriptions for this class of agents has continued to rise in 
recent  years
10.  Gingival  overgrowth  associated  with 
nifedipine was first reported in the early 1980s and was soon 
also described  with diltiazem, verapamil, and in rare cases 
with amlodipine and felodipine 
Immunosuppressants 
Cyclosporin  A  (CsA)  is  a  powerful  immunosuppressant 
widely used for prevention of transplant rejection as well as 
for management of a number of autoimmune conditions such 
as  rheumatoid  arthritis
17,18.  Successful  use  of  CsA  in 
transplant medicine has been limited by the development of 
prominent renal, cardiac, and gingival fibrosis
19-22. Renal and 
cardiac  lesions  may  be  so  severe  as  to  cause  transplant 
failure
20-22. Gingival lesions were reported as soon as results 
of the first clinical trials of this medication were published, 
and were more systematically examined in the 1980s. 
Drugs  commonly  associated  with  gingival  overgrowth,  by 
category and Indian brand names are given in Table 1. 
 
Table 1. Drugs commonly associated with gingival overgrowth 
CATEGORY  DRUGS  BRAND NAMES 
Anti-epileptics  Phenytoin  
Phenobarbitone  
Primidone 
Valproic acid 
Dilantin, Eptoin 
Gardinal, Phenetone 
Mysoline 
Valprid, Valtec, Valprin 
Calcium  Channel 
Blockers 
Dihydropyridines 
 
 
 
 
Phenylalkylamine 
Benzothiazepine 
 
Nifedipine 
Amlodipine 
Felodipine 
Nitrendipine 
Nicardipine 
Verapamil 
Diltiazem 
Bepridilhydrochloride  
 
Adalat, Caligard,Depin 
Amcard,Amdepin,Amlo 
Felogard,Penedil 
Nitrepin,Cardif 
Nicapress-R, Cardene 
Calaptin,Vasoplan 
Dilzem,Dilgard,Angizem 
Bepricor 
Immunosuppressant   Cyclosporine  Cyclomune,  Graftin, 
Cyclophil 
Miscellaneous  Erythromycin 
Sertraline  
Althrocin,Elucin 
Actiser,Daxid,Setalin 
 
 
CLINICAL  MANIFESTATIONS  OF  GINGIVAL 
ENLARGEMENT 
Clinical  manifestation  of  gingival  enlargement  frequently 
appears within 1 to 3 months after initiation of treatment with 
the associated medications
23. Gingival overgrowth normally 
begins  at  the  interdental  papillae  and  is  more  frequently 
found  in  the  anterior  segment  of  the  labial  surfaces
10,16. 
Gradually, gingival lobulations are formed that may appear 
inflamed or more fibrotic in nature, depending on the degree 
of  local  factor-induced  inflammation.  The  fibrotic 
enlargement normally is confined to the attached gingiva but 
may  extend  coronally  and  interfere  with  esthetics, 
mastication, or speech
10,16. 
Disfiguring  gingival  overgrowth  triggered  by  these 
medications  is  not  only  esthetically  displeasing  but  often 
impairs nutrition and access for oral hygiene, resulting in an 
increased  susceptibility  to  oral  infection,  caries,  and 
periodontal diseases
18.  
Most  drug-associated  gingival  enlargements  appear  to  be 
clinically indistinguishable, with the possible  exceptions of 
phenobarbitone
14  and  CsA
12.  In  phenobarbitonetreated 
patients,  the  gingiva  may  be  enlarged  uniformly  without 
lobulations  of  the  interdental  papillae,  and  severity  of  the 
clinical  lesions  has  been  reported  to  be  greater  in  the 
posterior as compared to the anterior regions
14. In individuals 
immunosuppressed with CsA, sometimes pebbly or papillary 
lesions appear on the surface of larger lobulations
24, which 
have been associated with the presence of Candida hyphae 
invading the gingival epithelium
24,25. Other investigators have 
reported  that  tissues  affected  by  CsA  are  generally  more 
hyperemic and bleed more readily upon probing than tissues 
affected by phenytoin
12. 
HISTOPATHOLOGY OF THE LESION 
An  ultrastructural  study  demonstrated  that  the  increase  in 
gingival tissue volume is primarily due to a connective tissue 
response rather than epithelial cell layer involvement
26. The 
histopathology of the lesions in all drug categories is similar 
and  is  characterized  by  excessive  accumulation  of 
extracellular matrix proteins, such as collagen, or amorphous 
ground substance
10,11,16. 
Varying  degrees  of  inflammatory  infiltrate  exist,  while  an 
increase in the number of fibroblasts remains controversial
27-
29. The predominant type of infiltrating inflammatory cell is 
the  plasma  cell.  Parakeratinized  epithelium  of  variable 
thickness covers the connective tissue stroma, and epithelial 
ridges may penetrate deep into the connective tissue, creating 
irregularly arranged collagen fibers
26. 
TREATMENT 
Drug substitution 
One  of  the  foundations  of  treatment  of  all  drug  induced 
gingival  overgrowths  is  drug  substitution.  Substitution  of 
Phenytoin  (PHT)  with  a  different  anticonvulsant  drug  has 
long  been  advocated  as  treatment  of  gingival  overgrowth. 
The  feasibility  of  drug  substitution has  increased  in recent 
times with the addition a new generation of anticonvulsant 
drugs  such  as  vigabatrin  (Sabril),  lomatrigine  (Lamictal), 
gabapentin (Neurontin), sulthiame (Ospolot) and topiramate 
(Topamax).  Reduction  of  gingival  overgrowth  after 
withdrawal  of  PHT  has  been  reported
30  and  complete 
regression  after  six  months  has  been  described  in  a  small 
group of children
31.  Reduction in the dose of Cyclosporine 
(Cs) has been shown to be beneficial
32,however, the nature of 
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reduction  is  not  available.  Some  patients  can  use  more 
conventional  immunosuppressants  such  as  steroids  and 
azothioprine  but  survival  rates  are  not  as  good.  New 
immunosuppressants such as tacrolimus (FK506) (Prograf), 
rapamycin and mycophenolate mofetil (MMF) CellCept may 
offer some hope, as to date these have not been reported in 
association  with  gingival  overgrowth.  Withdrawal  and 
substitution of the drug along with improved oral hygiene has 
been  successful  in  many  cases  of  nifedipine  gingival 
overgrowth
33,34. Unfortunately, not all cases respond to this 
treatment  ,  particularly  patients  with  long-standing 
overgrowth
35. In a similar manner, drug substitution has been 
effective  in  some  cases  of  gingival  overgrowth  due  to 
verapamil
36,  amlodipine
37  and  felodipine
38.  It  should  be 
remembered that the conditions for which patients are taking 
these drugs can be  very difficult to control and physicians 
may  be  very  reluctant  to  modify  an  effective  drug regime 
‘just for the gums’. Thus, while it is worth asking if drug 
substitution is possible, the dentist should understand that a 
negative  response  is  not  necessarily  a  disregard  for  the 
gingival  problem,  but  rather  a  concern  for  the  debilitating 
effects of the underlying condition. 
Oral hygiene 
Although the role of plaque has not been clearly defined in 
most  medication-induced  gingival  overgrowth,  there  is  no 
doubt that the resulting gingival inflammation can contribute 
an additional level of enlargement due to oedema, regardless 
of  any  initiating  or  contributing  effect  it  may  have  on 
gingival  overgrowth.  Control  of  this  inflammatory 
component of the gingival over growth , while important in 
itself,  also  aids  in  determining  if  surgical  reduction  is 
necessary and, additionally, allows for a less haemorrhagic 
field in any subsequent surgical intervention. 
A programme of intense oral hygiene failed to prevent the 
onset  of  Cs-induced    gingival  over  growth  nor  was  it 
particularly effective at reducing existing overgrowth
39, but 
was  of  some  benefit  for  general  periodontal  health,as 
expected. Chlorhexidine (0.12 per cent) mouthrinse has been 
reported  to  reverse  recurrent  Cs  overgrowth  following 
gingivectomy
40 and a study in rats indicates it may have a 
role  in  limiting  but  not  preventing  gingival  overgrowth
41, 
however, the side effects of long-term chlorhexidine have to 
be considered. Pernu and others
42 have shown that gingival 
bleeding increases the relative risk of gingival overgrowth in 
patients  taking  Cs.  Patients  receiving  nifedipine  do  not 
respond  to  conventional  treatment  as  well  as  patients  not 
taking the drug
43 . The role of plaque in nifedipine-induced 
gingival  overgrowth  is  uncertain  as  no  convincing 
longitudinal studies have investigated its role.  It is difficult 
to draw conclusions regarding the role of plaque in verapamil 
gingival  overgrowth.  Two  of  the  reported  cases
44,45    had 
significant  levels  of  plaque  but  many  patients  taking 
verapamil  have  high  levels  of  plaque  and  no  overgrowth. 
Good oral hygiene failed to reduce such overgrowth reported 
in children. Little information is available regarding plaque 
control and the other Calcium Channel Blockers (CCBs) but 
it  is  assumed  that  the  situation  would  be  similar  to  those 
mentioned. 
Surgical treatment 
The need for, and timing of, any surgical intervention needs 
to be carefully assessed. Surgery is normally performed for 
cosmetic/aesthetic  needs  before  any  functional  need  is 
manifested. In cases where drug therapy is likely to continue 
for  many  years  ,  psychosocial  considerations  need  to  be 
considered in an effort to reduce the frequency and extent of 
any  surgical  intervention.  While  classical  external  bevel 
gingivectomy  is  still  a  viable  treatment  option,  the  large 
denuded connective tissue wound that results can be painful 
and requires careful postoperative care to prevent infection. 
There is a tendency towards the use of either a total or partial 
internal bevel gingivectomy approach. This technically more 
demanding  approach  has  the  benefit  of  allowing  ‘primary 
closure’  thus  reducing  the  chances  of  postoperative 
complications, however,  it requires  more  time  and  skill to 
accomplish.  Surgical  treatment  of  PHT-  ,  Cs-  and  CCB-
induced gingival overgrowth has centred on gingivectomy by 
conventional  methods  and,  more  recently,  the  use  of  CO2 
lasers
46,47. The CO2 laser has been advocated because of the 
decreased surgical time, rapid postoperative haemostasis and 
the  fact  that  often  the  underlying  medical  conditions  are 
relative contraindications for conventional surgery. 
Surgical excision has been tried in non-responding nifedipine 
cases
48  and it has been successful when combined with good 
oral  hygiene
49.  Similar  results  have  been  found  with 
verapamil
45, and diltiazem gingival overgrowth, although it 
does recur
50. Most reports of amlodipine gingival overgrowth 
have  also  required  surgical  intervention  .  The  only  other 
reported  case  of  felodipine  gingival  over  growth  received 
careful  plaque  control  and  surgical  excision  of  the  most 
prominent gingival tissue, however, the authors did not state 
how effective this therapy was
51. 
CONCLUSION 
Three  types  of  pharmacologic  agents,  anticonvulsants, 
calcium channel blockers and immunosuppressants have been 
reported  to  cause  gingival  enlargement  in  susceptible 
individuals.  The  histologic  response  of  the  gingival 
connective tissue to these agents is uniformly characterized 
by an increase in the amount of collagen fibers as well as 
noncollagenous  proteins.    When  all  the  evidence  is 
considered, there appears to be three significant factors which 
are  important  in  the  expression  of  these  gingival  changes, 
notably  drug  variables,  plaque  –  induced  inflammatory 
changes  in  the  gingival  tissues  and  genetic  factors  which 
determine the heterogeneity of the fibroblast. 
Prevention and treatment includes meticulous plaque control 
and  frequent  professional  debridement.  Furthermore, 
respective  gingival  procedures  may  be  needed  to  improve 
function,  aesthetics  and  access  for  home  care.  The 
periodontist is restricted in controlling gingival inflammation, 
correcting  gingival  contour  and  treating  any  pre-existing 
periodontal  disease.  Ideally,  all  patients  about  to  be 
medicated with cyclosporine, phenytoin or a calcium channel 
blocker, should go through a full periodontal assessment and 
any disease present treated appropriately. 
Physicians  should  be  able  to  identify  changes  in  the  oral 
cavity related to the health of their patients. Unfortunately, 
most  medical  education  curricula  do  not  include  sufficient 
information for the physician to appreciate oral biology and 
oral  pathology.  Thus,  there  is  a  great  need  for  dental 
medicine and general medicine to work together in the care 
of drug induced gingival enlargement. 
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